

Vikram Arya, Fcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8892418/publications.pdf>

Version: 2024-02-01

30
papers

815
citations

706676

14
h-index

563245

28
g-index

31
all docs

31
docs citations

31
times ranked

1094
citing authors

#	ARTICLE	IF	CITATIONS
1	Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 61-65.	1.5	6
2	Role of Physiologically Based Pharmacokinetic Modeling and Simulation in Enabling Model-Informed Development of Drugs and Biotherapeutics. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S7-S11.	1.0	4
3	Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine-Drug Interactions. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 282-293.	1.3	20
4	A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 310-321.	1.3	14
5	Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1049-1060.	1.0	10
6	Cobicistat-containing antiretroviral regimens are not recommended during pregnancy. <i>Aids</i> , 2019, 33, 1089-1093.	1.0	27
7	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 836-864.	2.3	141
8	Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 578-580.	2.3	9
9	Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1295-1304.	1.0	13
10	Evaluation of transporters in drug development: Current status and contemporary issues. <i>Advanced Drug Delivery Reviews</i> , 2017, 116, 100-118.	6.6	62
11	Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 541-547.	1.0	3
12	Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S59-72.	1.0	85
13	The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S122-31.	1.0	45
14	Role of Transporters in Drug Development. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S7-S10.	1.0	8
15	Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 278-281.	1.5	3
16	Does an Increase in Serum Creatinine always Reflect Renal Injury? The Case of Stribild®. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 279-281.	1.0	8
17	Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 446-453.	0.3	8
18	Review of P-gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed $[I_{sub>1</sub>}/IC_{sub>50</sub>}]$ and $[I_{sub>2</sub>}/IC_{sub>50</sub>}]$ Criteria in the P-gp Decision Tree. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 228-233.	1.0	52

#	ARTICLE	IF	CITATIONS
19	Scientific Considerations for Pharmacoenhancers in Antiretroviral Therapy. Journal of Clinical Pharmacology, 2012, 52, 1128-1133.	1.0	9
20	Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation. Journal of Clinical Pharmacology, 2012, 52, 91S-108S.	1.0	91
21	Optimizing Drug Development and Use in Patients With Kidney Disease: Opportunities, Innovations, and Challenges. Journal of Clinical Pharmacology, 2012, 52, 4S-6S.	1.0	4
22	Regulatory Perspectives on Designing Pharmacokinetic Studies and Optimizing Labeling Recommendations for Patients With Chronic Kidney Disease. Journal of Clinical Pharmacology, 2012, 52, 79S-90S.	1.0	28
23	Optimizing Drug Development and Use in Patients With Kidney Disease. Journal of Clinical Pharmacology, 2011, 51, 628-630.	1.0	2
24	Brain permeability of inhaled corticosteroids. Journal of Pharmacy and Pharmacology, 2010, 57, 1159-1167.	1.2	17
25	Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics. Journal of Pharmacy and Pharmacology, 2010, 59, 1473-1484.	1.2	3
26	The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti-Influenza Drug, Peramivir. Clinical Pharmacology and Therapeutics, 2010, 88, 587-589.	2.3	25
27	Slow Release Formulations of Inhaled Rifampin. AAPS Journal, 2008, 10, 342-348.	2.2	70
28	Pulmonary targeting of sustained release formulation of budesonide in neonatal rats. Journal of Drug Targeting, 2006, 14, 680-686.	2.1	11
29	CONTRARY TO ADULT, NEONATAL RATS SHOW PRONOUNCED BRAIN UPTAKE OF CORTICOSTEROIDS. Drug Metabolism and Disposition, 2006, 34, 939-942.	1.7	20
30	Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: Effect of different routes of administration. AAPS Journal, 2004, 6, 68-73.	2.2	17